TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30092157
Drug: 400 IU/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 IU/day vitamin D (cholecalciferol) administered as a stat dose of 36,000 IU every three months.
Study: 24770498
Drug: Topical potassium
Normalized name: Topicale
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical potassium hydroxide therapy
Study: 20458465
Drug: Transcutaneous electrical
Normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous electrical tibial nerve stimulation (TTNS) in addition to standard therapy (bladder retraining and pelvic floor muscle exercises)
Study: 20458465
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (bladder retraining and pelvic floor muscle exercises)
Study: 12483094
Drug: Latanoprost 0.005%
Normalized name: LATANOPROST 0.005% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost 0.005% once daily for 8 weeks
Study: 12483094
Drug: Isopropyl unoprostone
Normalized name: isopropyl unoprostone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isopropyl unoprostone 0.12% twice daily for 8 weeks
Study: 10682558
Drug: Epimedium compound
Normalized name: Epimedium grandiflorum top extract
DrugBank: Epimedium grandiflorum top (DB14301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epimedium compound granules
Study: 589554
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy including vincristine at 3-week intervals
Study: 589554
Drug: Other therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other therapies or no therapy
Study: 26179284
Drug: Probiotics (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (a widely available food supplement with a low risk safety profile)
Study: 21311504
Drug: 60,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60,000 IU monthly oral vitamin D(3) for 16 weeks
Study: 15652899
Drug: Isolated isoflavones
Normalized name: ISOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isolated isoflavones (114 mg daily for 3 months)
Study: 9689393
Drug: Pancuronium (0.09
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium (0.09 mg kg‐1, n = 10)
Study: 9689393
Drug: Pipecuronium (0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pipecuronium (0.08 mg kg‐1, n = 10)
Study: 9689393
Drug: Atracurium (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium (0.6 mg kg‐1, n = 10)
Study: 9689393
Drug: Vecuronium (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium (0.1 mg kg‐1, n = 10)
Study: 7857439
Drug: Intracervical prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracervical prostaglandin E2 (PGE2) 0.5 mg
Study: 7857439
Drug: Intravenous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oxytocin (if labor not established)
Study: 2678652
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg tolfenamic acid
Study: 30779718
Drug: Daily fluid
Normalized name: ENSULIZOLE 4 g in 100 mL / OCTINOXATE 5 g in 100 mL / OCTOCRYLENE 10 g in 100 mL / TITANIUM DIOXIDE 5 g in 100 mL / OCTISALATE 5 g in 100 mL TOPICAL CREAM [EXEL CLARIFYING LINE DAILY FLUID SUN SHIELD WHITE COLOR BROAD SPECTRUM SPF 60 PLUS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily fluid balance, tidal volume, plateau pressure, positive end-expiratory pressure
Study: 23996292
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg ketoprofen in 4.4 g transfersome gel (IDEA-033)
Study: 23996292
Drug: 4.4 g
Normalized name: ALUMINUM CHLOROHYDRATE 4.4 g in 1 mg BUCCAL EMULSION [Antiperspirant]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.4 g ketoprofen-free vehicle (TDT 064)
Study: 21756276
Drug: Colour Doppler
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colour Doppler ultrasonography with SonoVue™ contrast agent
Study: 16995327
Drug: Valdecoxib (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valdecoxib (20 mg, o.d.)
Study: 16995327
Drug: Rofecoxib (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib (25 mg, o.d.)
Study: 12734781
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (overweight subgroup)
Study: 12734781
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin (overweight subgroup)
Study: 9876706
Drug: Intermittent intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent intramuscular injection of morphine
Study: 31004689
Drug: Balance training
Normalized name: Rebalance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balance training (exercised twice a week for 12 weeks)
Study: 25586727
Drug: Fibrinogen concentrate
Normalized name: Fibrinogen concentrate human
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinogen concentrate (2 g or equivalent)
Study: 19549431
Drug: Ciclesonide 80
Normalized name: CICLESONIDE 80MCG 60D ORAL INHL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclesonide 80 microg twice daily (CIC80 b.i.d.)
Study: 19549431
Drug: Ciclesonide 160
Normalized name: CICLESONIDE 160MCG 60D ORAL INHL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclesonide 160 microg once daily (CIC160 q.d.)
Study: 19549431
Drug: Ciclesonide treatments
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclesonide treatments (CIC80 b.i.d. and CIC160 q.d.)
Study: 16428009
Drug: Standard vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard vaccine information sheets
Study: 11348454
Drug: Long-term (192
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-term (192 wk) all‐trans retinoic acid treatment (n = 5)
Study: 9237602
Drug: Beta Blockers
Normalized name: BETA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta Blockers (BB)
Study: 26911315
Drug: Polyunsaturated fatty
Normalized name: omega-3 polyunsaturated fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyunsaturated fatty acids (PUFA) lotion 12%
Study: 22305830
Drug: RLX030 (recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: RLX030 (recombinant form of human relaxin 2) 30 μg/kg per day IV infusion for 48 hours
Study: 20132129
Drug: Octreotide infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide infusion (30 ng (kg min)(‐1))
Study: 20132129
Drug: Control (sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (sodium chloride infusion)
Study: 12514144
Drug: Desmopressin (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin (0.3 micro g x kg(‐1) infused intravenously over 20 min)
Study: 1510006
Drug: 0.05 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg/kg diltiazem
Study: 1510006
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg diltiazem
Study: 1510006
Drug: 0.25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg diltiazem
Study: 1510006
Drug: 0.45 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.45 mg/kg diltiazem
Study: 1510006
Drug: Diltiazem (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (0.15 to 0.45 mg/kg)
Study: 6090367
Drug: MDF (6141
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDF (6141 cGy, 69 fractions, 4 1/2 weeks, at 89 cGy every 4 hours 3 times daily)
Study: 6090367
Drug: MDF plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDF plus MISO (1.25 gm/M2 three times weekly for the first 3 weeks)
Study: 6090367
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose MDF (7120 cGy, 80 fractions, 5 1/2 weeks, at 89 cGy per fraction every 4 hours 3 times daily)
Study: 27652585
Drug: Sham feeding
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham feeding with gum chewing (two pieces of xylitol flavored gum for 15 minutes, three times a day after extubation until oral nutrition was tolerated)
Study: 24964348
Drug: Setipiprant 1000
Normalized name: Setipiprant
DrugBank: Setipiprant (DB12562)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Setipiprant 1000 mg b.i.d. for 5 days
Study: 21979440
Drug: 60 g
Normalized name: aspirin 60 Grains
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 g glucose dose after an overnight fast
Study: 21979440
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g glucose dose after a 2-hour fast
Study: 17311061
Drug: TPN with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPN with glutamine (0.3 g/kg/days)
Study: 2643904
Drug: Sustained-release theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release theophylline (THEO)
Study: 2643904
Drug: Inhaled bitolterol
Normalized name: bitolterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled bitolterol (BITOL)
Study: 1146718
Drug: Micronor (progestogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronor (progestogen type oral contraceptive)
Study: 1146718
Drug: Ortho‐Novum SQ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ortho‐Novum SQ (sequential type oral contraceptive)
Study: 1146718
Drug: Control cycle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control cycle (no oral contraceptives)
Study: 23816814
Drug: levocetirizine hydrochloride
DrugBank: Levocetirizine (DB06282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: levocetirizine hydrochloride 5 mg (Xyzal®) administered on day 8 after placebo for 7 days (treatment B)
Study: 23816814
Drug: levocetirizine hydrochloride
DrugBank: Levocetirizine (DB06282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: levocetirizine hydrochloride 5 mg (Xyzal®) administered for 8 days (treatment C)
Study: 23816814
Drug: placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo administered for 8 days (treatment A)
Study: 19267954
Drug: Sham-fed meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham-fed meal 2 (oral-stimulation)
Study: 17224218
Drug: MMR vaccine
Normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMR vaccine in combination with varicella (MMR and V)
Study: 15169694
Drug: Risperidone (1‐6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (1‐6 mg/day)
Study: 9572210
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate 2.5 mg + E1 sulfate 1.25 mg
Study: 9572210
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate 5 mg + E1 sulfate 1.25 mg
Study: 9572210
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate 10 mg + E1 sulfate 1.25 mg
Study: 7999348
Drug: Behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral treatment of depression in dementia patients
Study: 2741997
Drug: Sensorimotor integrative
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sensorimotor integrative treatment
Study: 30101636
Drug: Conventional treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment, biologics, and no treatment
Study: 22211956
Drug: Alfuzosin 10
Normalized name: Alfuzosin 10mg Oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin 10 mg + Sildenafil 50 mg
Study: 20304413
Drug: High protein,
Normalized name: Ensure High Protein, Banana, Instant
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein, low carbohydrate diet (20 g/d)
Study: 8758170
Drug: Thiopentone 5
Normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiopentone 5 mg.kg‐1 preceded by 40 mg of topical lignocaine spray
Study: 8758170
Drug: Propofol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2.5 mg.kg‐1 alone
Study: 2206072
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 chip (3.0 mg)
Study: 30816331
Drug: Weekly doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly doxorubicin
Study: 26077176
Drug: Sapropterin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sapropterin (5 mg/kg/day increased to 10 mg/kg on day 8)
Study: 24717838
Drug: Brivaracetam single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivaracetam single dose (2.5-100 mg)
Study: 24717838
Drug: Brivaracetam multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivaracetam multiple dose (2.5-50 mg twice daily)
Study: 22791079
Drug: Biotin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biotin (1 mg/day)
Study: 17013636
Drug: Active tea
Normalized name: IODINE 100 g in 100 g TOPICAL CREAM [Active Teat Cream]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active tea treatment (n = 37)
Study: 11940691
Drug: Nimesulide 100
Normalized name: nimesulide 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide 100 mg by mouth twice daily
Study: 7631673
Drug: Observation phase
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Observation phase (no treatment)
Study: 7631673
Drug: Treatment phase
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment phase (clindamycin 300 mg orally twice daily for 7 days)
Study: 7631673
Drug: Treatment phase
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment phase (clindamycin for bacterial vaginosis and trichomoniasis)
Study: 30517071
Drug: Intensive preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive preventive protocol (subgroups A1, B1, C1) including topical application of fluoride, brushing with 5000-ppm fluoride toothpaste, use of amorphous calcium phosphate-casein phosphopeptide, applications of sealants for occlusal lesions (ICDAS code 2), and minimal resin restorations for occlusal lesions (ICDAS code 3)
Study: 30517071
Drug: Instructions in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instructions in oral hygiene (subgroups A2, B2, C2)
Study: 30517071
Drug: Instructions in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instructions in oral hygiene (subgroup C2)
Study: 25826741
Drug: Nitrate supplementation
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate supplementation (beetroot juice; 5 mm, 0.45 g nitrates per day for 3 days)
Study: 25826741
Drug: Control (Ringer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Ringer solution)
Study: 8194141
Drug: Subcutaneous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous morphine infusion
Study: 2694339
Drug: Chloramphenicol (total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloramphenicol (total daily dosage, 2 g) plus placebo
Study: 2694339
Drug: Furazolidone (total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furazolidone (total daily dosage, 800 mg) plus placebo
Study: 846510
Drug: Hyaluronidase treatment
Normalized name: Hyaluronidase
DrugBank: Hyaluronidase (DB14740)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Hyaluronidase treatment (administered intravenously after the first electrocardiogram and every six hours for 48 hours)
Study: 846510
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no hyaluronidase treatment)
Study: 846510
Drug: Hyaluronidase treatment
Normalized name: Hyaluronidase
DrugBank: Hyaluronidase (DB14740)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Hyaluronidase treatment
Study: 11589259
Drug: Codeine 60
Normalized name: codeine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine 60 mg/acetaminophen 600 mg
Study: 27348762
Drug: Candesartan (32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (32 mg/d)
Study: 17647145
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir (0.15, 0.3, 0.6 U/kg)
Study: 17647145
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin (0.15, 0.3, 0.6 IU/kg)
Study: 10550081
Drug: Insulin four
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin four times daily regimen
Study: 10550081
Drug: Insulin twice
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin twice daily regimen
Study: 7607776
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of self-report, urinalysis, and hair analysis
Study: 2254836
Drug: Clindamycin hydrochloride
Normalized name: Clindamycin Hydrochloride
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin hydrochloride as an adjunct to scaling
Study: 26846356
Drug: Topical steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroids alone (Group A)
Study: 26846356
Drug: Topical and
Normalized name: norgestimate and ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical and oral steroids (Group B)
Study: 7871235
Drug: Brief treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief treatment sessions
Study: 2970498
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of lithium and imipramine
Study: 31075462
Drug: Anticoagulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation therapy (without filter placement)
Study: 26493425
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy (10 sessions of 90 minutes)
Study: 23872222
Drug: Fludarabine 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine 120 mg/m(2) + Melphalan 100 mg/m(2) (FM100)
Study: 23872222
Drug: Fludarabine 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine 120 mg/m(2) + Melphalan 140 mg/m(2) (FM140)
Study: 16579891
Drug: Sublingual misoprostol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual misoprostol, 600 g
Study: 16278618
Drug: E(2) 1
Normalized name: vitamin E 1 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: E(2) 1 mg/NETA 0.5 mg
Study: 16278618
Drug: E(2) 1
Normalized name: vitamin E 1 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: E(2) 1 mg/NETA 0.25 mg
Study: 8196848
Drug: SCMC‐Lys (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCMC‐Lys (750 mg/die in a linctus formula for 10 days and 2.7 g in a granular formula once a day for a maximum of 15 days)
Study: 3148381
Drug: Intensive subcutaneous
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive subcutaneous insulin injections
Study: 20205606
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (SQT)
Study: 8707437
Drug: Indium‐111 monoclonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indium‐111 monoclonal antimyosin antibody imaging
Study: 2387950
Drug: Calcium (1.558
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1.558 g) and vitamin D (45 micrograms or 1,800 IU) administered daily for 11 weeks
Study: 7325347
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg Buprenorphine (Temgesic)
Study: 7325347
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Nicomorphine (Vilan)
Study: 30771856
Drug: B-vitamin supplementation
Normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: B-vitamin supplementation (folic acid [5 mg], B12 [0.4 mg], B6 [50 mg])
Study: 23890764
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of naltrexone/disulfiram
Study: 19408641
Drug: Bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25% with tramadol 100 mg
Study: 16009749
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of telephone directories and religious sources
Study: 11914248
Drug: High-dose intracoronary
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intracoronary beta-radiation
Study: 9818750
Drug: Cefpirome (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefpirome (2 g bd iv)
Study: 9818750
Drug: Ceftazidime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (2 g tds iv)
Study: 4064532
Drug: Buscopan (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buscopan (20 mg)
Study: 798660
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Dantrium and Valium
Study: 26033972
Drug: rhBMP-12/ACS group
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhBMP-12/ACS group (0.015 mg/mL)
Study: 21455339
Drug: Aethoxysklerol injection
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aethoxysklerol injection
Study: 21455339
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hemoclip hemostasis with aethoxysklerol injection
Study: 17239277
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of differential expression, chromosomal alteration, and pathways signature analysis
Study: 11774270
Drug: Screening for
Normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening for prostate cancer using serum prostate-specific antigen (PSA) and digital rectal examination (DRE) as an ancillary test.
Study: 9419169
Drug: Valaciclovir, 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valaciclovir, 8 g/day
Study: 9419169
Drug: Acyclovir, 3.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir, 3.2 or 0.8 g/day